

Table S1: Supplementary data on the clinical characteristics of children with *C. auris* infection or colonization.

Continent	Country	# of Cases	Age, Mean	Male Sex	Source	Treatment	Preterm	Underlying Conditions	Mortality	Reference
South America	Colombia	34	NA	64%	100% blood	47% amphotericin B 29% azoles 21% caspofungin	26%	100% Abx 82% CVC 82% respiratory support 59% malnutrition 56% TPN 32% corticosteroids 15% surgery 12% malignancy 3% renal disease	41%	Berrio et al. [31]
South America	Colombia	39	NA (19%) aged <1 yr)	NA	Blood, urine, respiratory, GI system	NA	NA	NA	NA	Escandon et al. [33]
South America	Colombia	8 ¹	16 d	NA	50% blood (75% with additional site: sternal surgical incision, peritoneal fluid and 1intravascular thrombus) 13% abdominal wall incision 13% peritoneal tip catheter 25% urine	13% fluconazole 63% caspofungin 25% fluconazole and caspofungin	13%	100% broad spectrum abx 88% cardiac anomalies 88% respiratory support 75% surgery 38% CVC 25% NEC	38%	Alvarado-Socarras et al. [30]
South America	Colombia	12 ²	34 d (median)	75%	100% blood	NA	50%	100% CVC 100% respiratory support 92% TPN 75% surgery 50% cardiac anomalies 33% corticosteroids	42%	Armstrong et al. [25]

								8% hemodialysis		
South America	Venezuela	13	<2 m and one aged 14 yr	46%	100% blood	31% fluconazole 15% caspofungin 8% voriconazole 31% caspofungin and voriconazole 8% fluconazole and anidulafungin 8% fluconazole, voriconazole and caspofungin 8% voriconazole, caspofungin and amphotericin B 8% voriconazole and caspofungin 8% amphotericin B and caspofungin 8% voriconazole, caspofungin and anidulafungin	61%	100% CVC 100% previous abx 85% sepsis/septic shock 46% abdominal surgery 15% HIE 8% ventriculitis 8% RDS 8% cardiac anomalies	31%	Calvo et al. [32]
Asia	Iran	1	14 yr	0%	Ear	Topical nystatin and oral terbinafine	0%	None	0%	Abastabar et al. [22]
Asia	Iran	1	2.5 yr	100%	CSF	Fluconazole, amphotericin B and flucytosine	0%	Congenital Immune-deficiency (CGD)	NA	Mirhendi et al. [29]
Asia	India	17	19 d	70%	88% blood (40% with additional site: CSF, eye, urine, wound) 6% urine 6% urine and respiratory tract	29% amphotericin B and micafungin 24% amphotericin B and voriconazole 18% voriconazole 12% micafungin and voriconazole 12% fluconazole 6% fluconazole and voriconazole	88%	100% CVC 94% TPN 82% sepsis and abx 82% respiratory support 47% surgery (abdominal in 75%) 29% RDS 12% cardiac anomalies	41%	Chandramati et al [42]
Asia	India	1	NA	NA	Blood	NA	NA	NA	NA	Kaur et al. [16]
Asia	India	5	9 d	60%	100% blood	40% micafungin 60% micafungin and voriconazole	100%	100% CVC 100% TPN 100% RDS 100% abx	80%	Ramya et al. [41]

								40% NEC 20% bacterial sepsis		
Asia	India	5	2 yr	20%	100% blood	60% amphotericin B 20% caspofungin 20% no treatment	40%	100% broad spectrum abx 80% CVC 80% immune-deficiency (ALL/neutropenia) 20% surgery 20% GI anomalies 20% cardiac anomalies 20% respiratory support 20% renal disease	40%	Chowdhary et al. [79]
Asia	India	3	<1 m	NA	NA	NA	NA	NA	67%	Singh et al. [28]
Asia	India	22	NA (27% <1m)	NA	100% blood	NA	18.2%	24%, 50% ³ surgery 44% CVC 44% respiratory support	40.9%	Chakrabarti et al. [31]
Asia	Bangladesh	13	<1 m	NA	100% blood	NA	NA	NA	NA	Dutta et al. [35]
Asia	Bangladesh	3	10 d	100%	100% blood	100% voriconazole	NA	100% broad spectrum abx	67%	Sathi et al. [26]
Asia	Pakistan	1	NA	100%	Blood	NA	NA	CVC broad spectrum abx	0%	Moin et al. [44]
Asia	Korea	3	NA	NA	Ear	NA	NA	NA	NA	Kim et al. [45]
Asia	South Korea	2	1 yr	50%	100% blood	Fluconazole and amphotericin B	0%	100% TPN 100% HIE 50% broad spectrum abx 50% CVC 50% respiratory support	50%	Lee et al. [34]

								50% HLH and chemotherapy 50% abdominal surgery		
Asia	Oman	2	1 yr	100%	100% blood	NA	NA	100% broad spectrum abx 100% urinary catheter 50% neutropenia	NA	Mohsin et al. [21]
Europe	Italy	1	1 d	0%	Axilla, skin, eyes and ears	Colonization	100%	Extreme prematurity HIE	100% ⁴	Mesini et al. [43]
South Africa	Gauteng province	47	NA (15% <1 m)	NA	100% blood	NA	NA	NA	NA	Shuping et al. [27]
South Africa	Gauteng province	15	NA (93% <1 m)	NA	100% blood	NA	NA	NA	NA	Chibabhai et al. [33]

Abx-Antibiotics, AmphoB- amphotericin B, CVC-central venous catheter, NA- not available, GI-gastrointestinal, NEC-necrotizing colitis, HIE-hypoxic ischemic encephalopathy, RDS- respiratory distress syndrome, CSF- cerebrospinal fluid, ALL-acute lymphocytic leukemia, CGD- chronic granulomatous disease, TPN-total parenteral nutrition, HLH-hemophagocytic lymphohistiocytosis.

¹ Four included in [17] [Dr. Rodriguez-Morales, Universidad Tecnológica de Pereira, Colombia, personal communication].

² Additional 8 aged 1-18 years without separate clinical data.

³ In neonates and non-neonates, respectively.

⁴ Unrelated to *C. auris* isolation.

References

16. Alvarado-Socarras, J.L.; Vargas-Soler, J.A.; Franco-Paredes, C.; Villegas-Lamus, K.C.; Rojas-Torres, J.P.; Rodriguez-Morales, A.J. A Cluster of Neonatal Infections Caused by *Candida auris* at a Large Referral Center in Colombia. *J. Pediatr. Infect. Dis. Soc.* **2021**, *10*, 549–555. <https://doi.org/10.1093/jpids/piaa152>.
17. Escandón, P.; Cáceres, D.H.; Espinosa-Bode, A.; Rivera, S.; Armstrong, P.; Vallabhaneni, S.; Berkow, E.L.; Lockhart, S.R.; Chiller, T.; Jackson, B.R.; et al. Notes from the Field: Surveillance for *Candida auris*—Colombia, September 2016–May 2017. *MMWR Morb. Mortal. Wkly. Rep.* **2018**, *67*, 459–460. <https://doi.org/10.15585/mmwr.mm6715a6>.
21. Mesini, A.; Saffioti, C.; Mariani, M.; Florio, A.; Medici, C.; Moscatelli, A.; Castagnola, E. First Case of *Candida auris* Colonization in a Preterm, Extremely Low-Birth-Weight Newborn after Vaginal Delivery. *J. Fungi* **2021**, *7*, 649. <https://doi.org/10.3390/jof7080649>.
22. Mirhendi, H.; Charsizadeh, A.; Aboutalebian, S.; Mohammadpour, M.; Nikmanesh, B.; de Groot, T.; Meis, J.F.; Badali, H. South Asian (Clade I) *Candida auris* meningitis in a paediatric patient in Iran with a review of the literature. *Mycoses* **2022**, *65*, 134–139. <https://doi.org/10.1111/myc.13396>.
25. Ramya, G.M.; Balakrishnan, U.; Chandrasekaran, A.; Abiramalatha, T.; Amboiram, P.; Sekar, U.; UshaDevi, R. *Candida auris*, an emerging pathogen—Challenge in the survival of microprimies. *Indian J. Med. Microbiol.* **2021**, *39*, 367–369. <https://doi.org/10.1016/j.ijmb.2021.03.025>.

26. Rodriguez, J.Y.; Le Pape, P.; Lopez, O.; Esquea, K.; Labiosa, A.L.; Alvarez-Moreno, C. *Candida auris*: A Latent Threat to Critically Ill Patients With Coronavirus Disease 2019. *Clin. Infect. Dis.* **2021**, *73*, e2836–e2837. <https://doi.org/10.1093/cid/ciaa1595>.
27. Armstrong, P.A.; Rivera, S.M.; Escandon, P.; Caceres, D.H.; Chow, N.; Stuckey, M.J.; Díaz, J.; Gomez, A.; Vélez, N.; Espinosa-Bode, A.; et al. Hospital-Associated Multicenter Outbreak of Emerging Fungus *Candida auris*, Colombia, 2016. *Emerg. Infect. Dis.* **2019**, *25*, 1339–1346. <https://doi.org/10.3201/eid2507.180491>.
28. Sathi, F.A.; Paul, S.K.; Ahmed, S.; Alam, M.M.; Nasreen, S.A.; Haque, N.; Islam, A.; Nila, S.S.; Afrin, S.Z.; Aung, M.S.; et al. Prevalence and Antifungal Susceptibility of Clinically Relevant *Candida* Species, Identification of *Candida auris* and *Kodamaea ohmeri* in Bangladesh. *Trop. Med. Infect. Dis.* **2022**, *7*, 211. <https://doi.org/10.3390/tropicalmed7090211>.
29. Shuping, L.; Mpembe, R.; Mhlanga, M.; Naicker, S.D.; Maphanga, T.G.; Tsotetsi, E.; Wadula, J.; Velaphi, S.; Nakwa, F.; Chibabhai, V.; et al. Epidemiology of Culture-confirmed Candidemia Among Hospitalized Children in South Africa, 2012–2017. *Pediatr. Infect. Dis. J.* **2021**, *40*, 730–737. <https://doi.org/10.1097/INF.0000000000003151>.
30. Singh, A.; Mukhopadhyay, S. 585 Changing trends of candida sepsis and its impact on neonates admitted in nicu: A prospective study from a tertiary centre in India. In *British Association of Perinatal Medicine and Neonatal Society*; BMJ Publishing Group Ltd.: London, UK; Royal College of Paediatrics and Child Health: London, UK, 2022; pp. A149.2–A150.
31. Berrio, I.; Caceres, D.H.; Coronell, R.W.; Salcedo, S.; Mora, L.; Marin, A.; Varón, C.; Lockhart, S.R.; Escandón, P.; et al. Bloodstream Infections With *Candida auris* Among Children in Colombia: Clinical Characteristics and Outcomes of 34 Cases. *J. Pediatr. Infect. Dis. Soc.* **2021**, *10*, 151–154. <https://doi.org/10.1093/jpids/piaa038>.
32. Calvo, B.; Melo, A.S.A.; Perozo-Mena, A.; Hernandez, M.; Francisco, E.C.; Hagen, F.; Meis, J.F.; Colombo, A.L. First report of *Candida auris* in America: Clinical and microbiological aspects of 18 episodes of candidemia. *J. Infect.* **2016**, *73*, 369–374. <https://doi.org/10.1016/j.jinf.2016.07.008>.
33. Chakrabarti, A.; Sood, P.; Rudramurthy, S.M.; Chen, S.; Jillwin, J.; Iyer, R.; Sharma, A.; Harish, B.N.; Roy, I.; Kindo, A.J.; et al. Characteristics, outcome and risk factors for mortality of paediatric patients with ICU-acquired candidemia in India: A multicentre prospective study. *Mycoses* **2020**, *63*, 1149–1163. <https://doi.org/10.1111/myc.13145>.
34. Chandramati, J.; Sadanandan, L.; Kumar, A.; Ponthenkandath, S. Neonatal *Candida auris* infection: Management and prevention strategies—A single centre experience. *J. Paediatr. Child Health* **2020**, *56*, 1565–1569. <https://doi.org/10.1111/jpc.15019>.
35. Chibabhai, V. Incidence of candidemia and prevalence of azole-resistant candidemia at a tertiary South African hospital—A retrospective laboratory analysis 2016–2020. *S. Afr. J. Infect. Dis.* **2022**, *37*, 326. <https://doi.org/10.4102/sajid.v37i1.326>.
41. Kullberg, B.J.; Arendrup, M.C. Invasive Candidiasis. *N. Engl. J. Med.* **2015**, *373*, 1445–1456. <https://doi.org/10.1056/NEJMra1315399>.
42. Pfaller, M.A.; Jones, R.N.; Castanheira, M. Regional data analysis of *Candida non-albicans* strains collected in United States medical sites over a 6-year period, 2006–2011. *Mycoses* **2014**, *57*, 602–611. <https://doi.org/10.1111/myc.12206>.
43. Guinea, J. Global trends in the distribution of *Candida* species causing candidemia. *Clin. Microbiol. Infect.* **2014**, *20* (Suppl. 6), 5–10. <https://doi.org/10.1111/1469-0691.12539>.
44. Pfaller, M.A.; Andes, D.R.; Diekema, D.J.; Horn, D.L.; Reboli, A.C.; Rotstein, C.; Franks, B.; Azie, N.E. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of *Candida* in 2496 patients: Data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. *PLoS ONE* **2014**, *9*, e0101510. <https://doi.org/10.1371/journal.pone.0101510>.
45. Arendrup, M.C.; Dzajic, E.; Jensen, R.H.; Johansen, H.K.; Kjaeldgaard, P.; Knudsen, J.D.; Kristensen, L.; Leitz, C.; Lemming, L.E.; Nielsen, L.; et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: Data from a nationwide fungaemia surveillance programme. *Clin. Microbiol. Infect.* **2013**, *19*, E343–53. <https://doi.org/10.1111/1469-0691.12212>.
79. Morales-López, S.E.; Parra-Giraldo, C.M.; Ceballos-Garzón, A.; Martínez, H.P.; Rodríguez, G.J.; Álvarez-Moreno, C.A.; Rodríguez, J.Y. Invasive Infections with Multidrug-Resistant Yeast *Candida auris*, Colombia. *Emerg. Infect. Dis.* **2017**, *23*, 162–164. <https://doi.org/10.3201/eid2301.161497>.